1 results match your criteria: "Centre François Baclesse (Institut Normand Du Sein)[Affiliation]"
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Breast
December 2020
Breast Cancer Unit, Centre François Baclesse (Institut Normand Du Sein), Caen, France.
Article Synopsis
- - The study aimed to evaluate the effectiveness and safety of combining eribulin with bevacizumab as a first-line treatment for HER2-negative metastatic breast cancer, comparing it to previous regimens like paclitaxel.
- - In a clinical trial involving 61 women, the combination treatment resulted in a 32% non-progression rate at one year and a median progression-free survival of 8.3 months, indicating promising results.
- - Adverse effects were reported, with hypertension (39%) and neutropenia (26%) being the most common serious side effects, but overall, the treatment was considered to have an acceptable safety profile with low rates of severe neuropathy.